Literature DB >> 19577079

Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis.

Pey-Jen Yu1, Adam Skolnick, Giovanni Ferrari, Katherine Heretis, Paolo Mignatti, Giuseppe Pintucci, Barry Rosenzweig, Juan Diaz-Cartelle, Itzhak Kronzon, Gila Perk, Harvey I Pass, Aubrey C Galloway, Eugene A Grossi, Juan B Grau.   

Abstract

OBJECTIVE: The inflammatory process of aortic stenosis involves the differentiation of aortic valve myofibroblasts into osteoblasts. Osteopontin, a proinflammatory glycoprotein, both stimulates differentiation of myofibroblasts and regulates the deposition of calcium by osteoblasts. Osteopontin levels are increased in patients with such conditions as end-stage renal disease, ectopic calcification, and autoimmune disease. We hypothesized that increased plasma osteopontin levels might be associated with the presence of aortic valve calcification and stenosis.
METHODS: Venous blood from volunteers older than 65 years undergoing routine echocardiographic analysis or aortic valve surgery for aortic stenosis was collected. Plasma osteopontin levels were measured by means of enzyme-linked immunosorbent assay. The presence of aortic stenosis was defined as an aortic valve area of less than 2.0 cm(2). Aortic valve calcification was assessed by using a validated echocardiographic grading system (1, none; 2, mild; 3, moderate; 4, severe). Comparisons were performed with nonpaired t tests.
RESULTS: Aortic stenosis was present in 23 patients (mean age, 78 years) and was absent in 7 patients (mean age, 72 years). Aortic valve calcification scores were 3.5 +/- 0.6 and 1.3 +/- 0.5 in patients with and without aortic stenosis, respectively (P < .001). Patients with no or mild aortic valve calcification had lower osteopontin levels compared with patients with moderate or severe aortic valve calcification (406.1 +/- 165.8 vs 629.5 +/- 227.5 ng/mL, P = .01). Similarly, patients with aortic stenosis had higher osteopontin levels compared with patients without aortic stenosis (652.2 +/- 218.7 vs 379.7 +/- 159.9 ng/mL, P < .01).
CONCLUSION: Increased levels of plasma osteopontin are associated with the presence of aortic valve calcification and stenosis. These findings suggest that osteopontin might play a functional role in the pathogenesis of calcific aortic stenosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577079     DOI: 10.1016/j.jtcvs.2008.10.045

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  27 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Calcium-binding nanoparticles for vascular disease.

Authors:  Deborah D Chin; Sampreeti Chowdhuri; Eun Ji Chung
Journal:  Regen Eng Transl Med       Date:  2018-10-23

3.  Validation of plasma biomarkers in degenerative calcific aortic stenosis.

Authors:  Giovanni Ferrari; Rachana Sainger; Erik Beckmann; Gianluca Keller; Pey-Jen Yu; Maria Cristina Monti; Aubrey C Galloway; Richard L Weiss; William Vernick; Juan B Grau
Journal:  J Surg Res       Date:  2010-05-06       Impact factor: 2.192

Review 4.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.

Authors:  William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

Review 5.  Drug Therapy for Heart Valve Diseases.

Authors:  Jeffrey S Borer; Abhishek Sharma
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

6.  Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Paolo Poggio; Emanuela Branchetti; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Giovanni Ferrari
Journal:  Biomarkers       Date:  2011-12-23       Impact factor: 2.658

Review 7.  Insights into the use of biomarkers in calcific aortic valve disease.

Authors:  Erik Beckmann; Juan B Grau; Rachana Sainger; Paolo Poggio; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2010-07

8.  Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis.

Authors:  Emanuela Branchetti; Rachana Sainger; Paolo Poggio; Juan B Grau; Jeffrey Patterson-Fortin; Joseph E Bavaria; Michael Chorny; Eric Lai; Robert C Gorman; Robert J Levy; Giovanni Ferrari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

Review 9.  Biomolecular mechanism of urinary stone formation involving osteopontin.

Authors:  Kenjiro Kohri; Takahiro Yasui; Atsushi Okada; Masahito Hirose; Shuzo Hamamoto; Yasuhiro Fujii; Kazuhiro Niimi; Kazumi Taguchi
Journal:  Urol Res       Date:  2012-11-06

10.  Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease.

Authors:  Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari
Journal:  Physiol Genomics       Date:  2020-02-24       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.